http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021030687-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2276405ae0e23cfcd15651de21c8565
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-10
filingDate 2019-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31afb1d025dbad4d0aa3e12cbd52d11f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a630b8332e8889e18bed8cfa5335fd7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f45a9df340b719701cada467de60f15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49ed93490288a76d99571edb4965e7ec
publicationDate 2021-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2021030687-A1
titleOfInvention Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
abstract The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.
priorityDate 2018-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9568614
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393946
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413481
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413480
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413482
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9568613
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9579578
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665634
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444041
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394003
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID237121371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4594
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226511144
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412622
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3423265
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413479
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87059199
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87059198

Total number of triples: 51.